×
About 2,565 results

ALLMedicine™ Generalized Tonic-clonic Seizures Center

Research & Reviews  419 results

Genetic generalized epilepsies in adults - challenging assumptions and dogmas.
https://doi.org/10.1038/s41582-021-00583-9
Nature Reviews. Neurology; Vorderwülbecke BJ, Wandschneider B et. al.

Nov 28th, 2021 - Genetic generalized epilepsy (GGE) syndromes start during childhood or adolescence, and four commonly persist into adulthood, making up 15-20% of all cases of epilepsy in adults. These four GGE syndromes are childhood absence epilepsy, juvenile ab...

Topiramate for juvenile myoclonic epilepsy.
https://doi.org/10.1002/14651858.CD010008.pub5
The Cochrane Database of Systematic Reviews; Liu J, Tai YJ et. al.

Nov 25th, 2021 - Topiramate is a newer broad-spectrum antiepileptic drug (AED). Some studies have shown the benefits of topiramate in the treatment of juvenile myoclonic epilepsy (JME). However, there are no current systematic reviews to determine the efficacy and...

A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalizat...
https://clinicaltrials.gov/ct2/show/NCT04252846

Nov 4th, 2021 - The primary purpose of this study is to assess the retention rate of perampanel as a reliable proxy for overall effectiveness and tolerability in participants aged at least 12 years who are prescribed perampanel (for partial onset seizures [POS] w...

Perampanel as first add-on antiseizure medication: Italian consensus clinical practice ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549193
BMC Neurology; Bonanni P, Gambardella A et. al.

Oct 28th, 2021 - When use of a single antiseizure medication (ASM) fails to induce seizure remission, add-on therapy is justified. Perampanel (PER) is approved in Europe as adjunctive therapy for focal, focal to bilateral tonic-clonic seizures and generalized toni...

Clinical and EEG factors associated with antiseizure medication resistance in idiopathi...
https://doi.org/10.1111/epi.17104
Epilepsia Kamitaki BK, Janmohamed M et. al.

Oct 28th, 2021 - We sought to determine which combination of clinical and electroencephalography (EEG) characteristics differentiate between an antiseizure medication (ASM)-resistant vs ASM-responsive outcome for patients with idiopathic generalized epilepsy (IGE)...

see more →

Guidelines  1 results

Practice guideline update summary: Efficacy and tolerability of the new antiepileptic d...
https://doi.org/10.1212/WNL.0000000000005755
Neurology Kanner AM, Ashman E et. al.

Jun 15th, 2018 - To update the 2004 American Academy of Neurology (AAN) guideline for treating new-onset focal or generalized epilepsy with second- and third-generation antiepileptic drugs (AEDs). The 2004 AAN criteria were used to systematically review literature...

see more →

Drugs  533 results see all →

Clinicaltrials.gov  9 results

A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalizat...
https://clinicaltrials.gov/ct2/show/NCT04252846

Nov 4th, 2021 - The primary purpose of this study is to assess the retention rate of perampanel as a reliable proxy for overall effectiveness and tolerability in participants aged at least 12 years who are prescribed perampanel (for partial onset seizures [POS] w...

Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Sei...
https://clinicaltrials.gov/ct2/show/NCT03059381

May 7th, 2021 - The objective of this study is to identify the following in adolescent epilepsy participants with partial-onset seizures (with or without secondary generalized seizures) or primary generalized Tonic-clonic seizures who receive long-term treatment ...

A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subject...
https://clinicaltrials.gov/ct2/show/NCT01463306

Jan 20th, 2021 - Study A0081106 is a 12-month open-label study to evaluate the long term safety and tolerability of pregabalin as add-on therapy in pediatric subjects 1 month to 16 years of age with partial onset seizures and pediatric and adult subjects 5 to 65 y...

Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures
https://clinicaltrials.gov/ct2/show/NCT00520741

Jul 19th, 2018 - Sudden unexplained death in epilepsy have been reported in epilepsy patients. A causal relationship with the administration of antiepileptic drugs has not been established. The most important known risk factor for sudden unexplained death in epile...

Detecting Generalized Tonic-Clonic Seizures With a Seizure Detection and Warning System in Epilepsy Patients
https://clinicaltrials.gov/ct2/show/NCT02371200

Jul 10th, 2018 - This study "A Pivotal, Phase III Trial of Detecting generalized tonic-clonic seizures with a Seizure Detection and Warning System in Epilepsy Patients " is a phase III, pivotal, prospective study of an electromyography (EMG) based seizure detectio...

see more →

News  63 results

A Sexually Active 23-Year-Old With Seizures and Tongue Pain
https://www.medscape.com/viewarticle/865890

Oct 5th, 2021 - Editor's Note: The Case Challenge series includes difficult-to-diagnose conditions, some of which are not frequently encountered by most clinicians but are nonetheless important to accurately recognize. Test your diagnostic and treatment skills us...

Seizure a First Sign of COVID in Kids?
https://www.medscape.com/viewarticle/958508

Sep 10th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Unlike in adults, seizures, including status epilepticus (SE), may be the first and main manifestation of COVID-19 in children, new research sugge...

Deeper Sleep, Slower Heart Rate Tied to Sudden Death in Epilepsy
https://www.medscape.com/viewarticle/951137

May 14th, 2021 - Deeper sleep and slower heart rate following seizures may work synergistically to increase the risk for sudden unexpected death in epilepsy (SUDEP), new research suggests. Investigators analyzed data on 100 seizures in 42 patients with epilepsy. T...

An Update on New Epilepsy Medications
https://www.medscape.com/viewarticle/949554

Apr 20th, 2021 - At the ongoing Academy of Neurology 2021 Annual Meeting, being held virtually on April 17-22, Joseph Sirven, MD, professor of neurology at the Mayo Clinic in Jacksonville, Florida, led an epilepsy course updating viewers on new epilepsy medication...

Little Evidence to Support Treatments for Prevention of Sudden Unexpected Death in Epilepsy
https://www.medscape.com/viewarticle/928854

Apr 17th, 2020 - NEW YORK (Reuters Health) - More research is needed to identify effective interventions aimed at preventing sudden unexpected death in patients with epilepsy (SUDEP), according to an updated Cochrane review. SUDEP occurs with an incidence of 1 to ...

see more →

Patient Education  1 results see all →